Safety and Efficacy of Catheter-Free Radioablation in Advanced Heart Disease

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  European Heart Journal https://doi.org/10.1093/eurheartj/ehag153
Dr. Tessa H Reitsmaet al.

Points

Researchers conducted a clinical study evaluating seven patients with advanced heart disease to determine if noninvasive proton beam therapy could safely reduce life-threatening episodes of ventricular tachycardia.
The investigation demonstrated a significant seventy-nine percent reduction in heart rhythm events with monthly episodes decreasing from over seven per patient down to just one point five post-treatment.
Unlike traditional radiation methods the precision of proton beams allowed clinicians to target abnormal heart tissue while successfully minimizing radiation exposure to healthy surrounding organs and vital heart structures.
Clinical data collected during a two-year follow-up period showed that heart function remained stable and there were no serious side effects directly related to the noninvasive radiation treatment.
These preliminary results suggest that catheter-free proton therapy is a feasible and safe alternative for patients with refractory arrhythmias who have already failed standard surgical and medical interventions.

Summary

This study evaluated the clinical feasibility and safety of catheter-free cardiac radioablation (CRA) using proton beam therapy for patients with refractory ventricular tachycardia (VT). Given that cardiovascular diseases remain a leading cause of mortality and many patients exhaust standard interventions like catheter ablation and antiarrhythmic pharmacotherapy, the research sought to determine if noninvasive proton irradiation could provide a superior alternative. The investigation utilized a highly targeted approach to deliver a single session of radiation to the arrhythmogenic substrate in seven patients with advanced heart disease.

The analysis revealed a significant reduction in life-threatening arrhythmias, with VT episodes decreasing by 79% from a baseline average of 7.2 episodes per month to 1.5 episodes per month post-treatment. Unlike conventional photon-based radiation, proton therapy permitted more precise targeting, which minimized exposure to healthy myocardium and surrounding thoracic organs. During a follow-up period of up to two years, key measures of cardiac function remained stable, and investigators found no definite evidence of associated toxicity or serious treatment-related adverse events.

The results suggest that proton-based CRA is a viable and effective disease-modifying therapy for patients with limited remaining options. While the cohort was small, the dramatic reduction in arrhythmic burden supports further investigation in larger prospective trials to establish long-term efficacy and safety. The findings also highlight the importance of early intervention and specialized risk assessment in complex heart failure cases. Integrating this noninvasive modality into clinical practice guidelines could potentially shift the treatment paradigm for advanced cardiac rhythm disorders and improve survival outcomes in high-risk populations.

Link to the article: https://www.heartrhythmjournal.com/article/S1547-5271(26)02271-X/abstract

References

Reitsma, T. H., Lim, C.-E., Gynnild, M. N., Kaptoge, S., Lõo, L., Holtrop, J., Kuźma, Ł., Pennells, L., Conrad, N., Ueda, P., Jernberg, T., Kurasz, A., Keene, S. J., Chilala, C., Deo, S. V., Tillmann, T., Khuncti, K., Piepoli, M., Rossello, X., … Wood, A. (2026). Prediction of incident heart failure in established atherosclerotic cardiovascular disease: The SMART2-HF model. European Heart Journal, ehag153. https://doi.org/10.1093/eurheartj/ehag153